Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
A one-shot gene-editing cholesterol therapy could soon be a reality
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
